Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02437318




Registration number
NCT02437318
Ethics application status
Date submitted
22/04/2015
Date registered
7/05/2015
Date last updated
18/11/2023

Titles & IDs
Public title
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Scientific title
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Secondary ID [1] 0 0
2015-000340-42
Secondary ID [2] 0 0
CBYL719C2301
Universal Trial Number (UTN)
Trial acronym
SOLAR-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Fulvestrant
Treatment: Drugs - Alpelisib
Treatment: Drugs - Alpelisib placebo

Experimental: fulvestrant + alpelisib - Alpelisib (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)

Placebo Comparator: fulvestrant + placebo - Placebo (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)


Treatment: Drugs: Fulvestrant


Treatment: Drugs: Alpelisib


Treatment: Drugs: Alpelisib placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort
Timepoint [1] 0 0
Once approximately 243 PFS events in this cohort had been observed, up to 32 months
Secondary outcome [1] 0 0
Overall Survival (OS) for Patients With PI3KCA Mutant Status
Timepoint [1] 0 0
Up to approximatly 59 months
Secondary outcome [2] 0 0
Overall Response Rate (ORR)
Timepoint [2] 0 0
Up to approximatly 36 months
Secondary outcome [3] 0 0
Time to Definitive Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status
Timepoint [3] 0 0
Baseline, Up to approximatly 36 months
Secondary outcome [4] 0 0
Safety and Tolerability of Alpelisib in Combination With Fulvestrant
Timepoint [4] 0 0
Up to approximatly 37 months
Secondary outcome [5] 0 0
Time to 10% Deterioration in the Global Health Status/Quality of Life (QOL) Scale Score of the EORTC QLQ-C30
Timepoint [5] 0 0
Up to approximatly 36 months
Secondary outcome [6] 0 0
Plasma Concentration-time Profile of Alpelisib Given in Combinatio With Fulvestrant and Appropriate Pharmacokinetics (PK) Parameters
Timepoint [6] 0 0
Day 8 and Day 15 of Cycle 1, then Day 1 of Cycles 2,4, 6, 8
Secondary outcome [7] 0 0
PFS Based on Radiology Assessments and Using RECIST 1.1 Criteria
Timepoint [7] 0 0
Baseline, Up to approximatly 36 months
Secondary outcome [8] 0 0
Clinical Benefit Rate (CBR)
Timepoint [8] 0 0
Up to approximatly 36 months
Secondary outcome [9] 0 0
Change in the Global Health Status/(QOL) Scale Score of the EORTC QLQ-C30
Timepoint [9] 0 0
Baseline, Up to approximatly 36 months
Secondary outcome [10] 0 0
Summary Statistics of Fulvestrant and Alpelisib Plasma Concentrations
Timepoint [10] 0 0
Day 8 and Day 15 of Cycle 1, then Day 1 of Cycles 2,4, 6, 8
Secondary outcome [11] 0 0
PFS for Patients With PIK3CA Non-mutant Status
Timepoint [11] 0 0
Up to approximatly 36 months
Secondary outcome [12] 0 0
OS for Patients With PIK3CA Non-mutant Status
Timepoint [12] 0 0
Up to approximatly 59 months

Eligibility
Key inclusion criteria
- If female, patient is postmenopausal

- Patient has identified PIK3CA status

- Patients may be:

- relapsed with documented evidence of progression while on (neo) adjuvant
endocrine therapy or within 12 months from completion of (neo)adjuvant endocrine
therapy with no treatment for metastatic disease;

- relapsed with documented evidence of progression more than 12 months from
completion of (neo)adjuvant endocrine therapy and then subsequently; progressed
with documented evidence of progression while on or after only one line of
endocrine therapy for metastatic disease;

- newly diagnosed advanced breast cancer, then relapsed with documented evidence of
progression while on or after only one line of endocrine therapy

- Patient has recurrence or progression of disease during or after AI therapy (i.e.

letrozole, anastrozole, exemestane).

- Patient has a histologically and/or cytologically confirmed diagnosis of
estrogen-receptor positive breast cancer by local laboratory and has HER2 negative
breast cancer

- Patient has either measurable disease per RECIST 1.1 criteria OR at least one
predominantly lytic bone lesion must be present

- Patient has adequate bone marrow function
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patient with symptomatic visceral disease or any disease burden that makes the patient
ineligible for endocrine therapy per the investigator's best judgment

- Patient has received prior treatment with chemotherapy (except for neoadjuvant/
adjuvant chemotherapy), fulvestrant, any PI3K, mTOR or AKT inhibitor (pre-treatment
with CDK4/6 inhibitors is allowed)

- Patient with inflammatory breast cancer at screening

- Patients with Child pugh score B or C

- Patients with an established diagnosis of diabetes mellitus type I or not controlled
type II

- Patient has Eastern Cooperative Oncology Group (ECOG) performance status 2 or more

- Patient with CNS involvement unless he/she is at least 4 weeks from prior therapy
completion to starting the study treatment and has stable CNS tumor at time of
screening and not receiving steroids and/or enzyme inducing ant-epileptic medications
for brain metastases

- Patient has participated in a prior investigational study within 30 days prior to
enrollment or within 5 half-lives of the investigational product, whichever is longer

- Patient has a history of acute pancreatitis within 1 year of screening or a past
medical history of chronic pancreatitis

- Patient who relapsed with documented evidence of progression more than 12 months from
completion of (neo)adjuvant endocrine therapy with no treatment for metastatic disease

Other protocol-defined inclusion/esclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/07/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
9/06/2023
Sample size
Target
Accrual to date
Final
572
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Wahroonga
Recruitment hospital [2] 0 0
Novartis Investigative Site - Wooloongabba
Recruitment hospital [3] 0 0
Novartis Investigative Site - Elizabeth Vale
Recruitment hospital [4] 0 0
Novartis Investigative Site - Melbourne
Recruitment postcode(s) [1] 0 0
2076 - Wahroonga
Recruitment postcode(s) [2] 0 0
4102 - Wooloongabba
Recruitment postcode(s) [3] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [4] 0 0
3000 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Montana
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Oregon
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
South Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
South Dakota
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Virginia
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
Argentina
State/province [23] 0 0
Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Viedma
Country [25] 0 0
Argentina
State/province [25] 0 0
La Rioja
Country [26] 0 0
Austria
State/province [26] 0 0
Linz
Country [27] 0 0
Austria
State/province [27] 0 0
Vienna
Country [28] 0 0
Belgium
State/province [28] 0 0
Antwerpen
Country [29] 0 0
Belgium
State/province [29] 0 0
Brussel
Country [30] 0 0
Belgium
State/province [30] 0 0
Oost Vlaanderen
Country [31] 0 0
Belgium
State/province [31] 0 0
Bruxelles
Country [32] 0 0
Belgium
State/province [32] 0 0
Libramont
Country [33] 0 0
Belgium
State/province [33] 0 0
Ottignies
Country [34] 0 0
Belgium
State/province [34] 0 0
Verviers
Country [35] 0 0
Brazil
State/province [35] 0 0
RN
Country [36] 0 0
Brazil
State/province [36] 0 0
RS
Country [37] 0 0
Brazil
State/province [37] 0 0
SP
Country [38] 0 0
Brazil
State/province [38] 0 0
Sao Jose do Rio Preto
Country [39] 0 0
Brazil
State/province [39] 0 0
Sao Paulo
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Plovdiv
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Sofia
Country [42] 0 0
Bulgaria
State/province [42] 0 0
Varna
Country [43] 0 0
Canada
State/province [43] 0 0
Alberta
Country [44] 0 0
Canada
State/province [44] 0 0
Ontario
Country [45] 0 0
Canada
State/province [45] 0 0
Quebec
Country [46] 0 0
Chile
State/province [46] 0 0
Araucania
Country [47] 0 0
Chile
State/province [47] 0 0
Santiago
Country [48] 0 0
Chile
State/province [48] 0 0
Vina del Mar
Country [49] 0 0
Czechia
State/province [49] 0 0
Czech Republic
Country [50] 0 0
Czechia
State/province [50] 0 0
Prague 8
Country [51] 0 0
France
State/province [51] 0 0
Bouches Du Rhone
Country [52] 0 0
France
State/province [52] 0 0
Angers 02
Country [53] 0 0
France
State/province [53] 0 0
Avignon
Country [54] 0 0
France
State/province [54] 0 0
Caen
Country [55] 0 0
France
State/province [55] 0 0
Clermont Ferrand
Country [56] 0 0
France
State/province [56] 0 0
Creteil
Country [57] 0 0
France
State/province [57] 0 0
La Roche sur Yon cedex 9
Country [58] 0 0
France
State/province [58] 0 0
Le Chesnay
Country [59] 0 0
France
State/province [59] 0 0
Levallois-Perret
Country [60] 0 0
France
State/province [60] 0 0
Lyon Cedex 08
Country [61] 0 0
France
State/province [61] 0 0
Montpellier
Country [62] 0 0
France
State/province [62] 0 0
Nimes
Country [63] 0 0
France
State/province [63] 0 0
Rouen
Country [64] 0 0
France
State/province [64] 0 0
Saint-Herblain Cédex
Country [65] 0 0
France
State/province [65] 0 0
Toulouse
Country [66] 0 0
France
State/province [66] 0 0
Villejuif Cedex
Country [67] 0 0
Germany
State/province [67] 0 0
North Rhine-westphalia
Country [68] 0 0
Germany
State/province [68] 0 0
Sachsen
Country [69] 0 0
Germany
State/province [69] 0 0
Schleswig-Holstein
Country [70] 0 0
Germany
State/province [70] 0 0
Aschaffenburg
Country [71] 0 0
Germany
State/province [71] 0 0
Frankfurt
Country [72] 0 0
Germany
State/province [72] 0 0
Friedrichshafen
Country [73] 0 0
Germany
State/province [73] 0 0
Hannover
Country [74] 0 0
Germany
State/province [74] 0 0
Homburg
Country [75] 0 0
Germany
State/province [75] 0 0
Kiel
Country [76] 0 0
Germany
State/province [76] 0 0
Mainz
Country [77] 0 0
Germany
State/province [77] 0 0
Potsdam
Country [78] 0 0
Germany
State/province [78] 0 0
Rostock
Country [79] 0 0
Germany
State/province [79] 0 0
Ulm
Country [80] 0 0
Germany
State/province [80] 0 0
Velbert
Country [81] 0 0
Greece
State/province [81] 0 0
GR
Country [82] 0 0
Greece
State/province [82] 0 0
Athens
Country [83] 0 0
Hong Kong
State/province [83] 0 0
Hong Kong
Country [84] 0 0
Hungary
State/province [84] 0 0
Budapest
Country [85] 0 0
Hungary
State/province [85] 0 0
Nyiregyhaza
Country [86] 0 0
Hungary
State/province [86] 0 0
Szekszard
Country [87] 0 0
India
State/province [87] 0 0
Andhra Pradesh
Country [88] 0 0
India
State/province [88] 0 0
Maharashtra
Country [89] 0 0
India
State/province [89] 0 0
Mumbai
Country [90] 0 0
Israel
State/province [90] 0 0
Beer-Sheva
Country [91] 0 0
Israel
State/province [91] 0 0
Haifa
Country [92] 0 0
Israel
State/province [92] 0 0
Petach Tikva
Country [93] 0 0
Israel
State/province [93] 0 0
Ramat Gan
Country [94] 0 0
Israel
State/province [94] 0 0
Tel Aviv
Country [95] 0 0
Italy
State/province [95] 0 0
AN
Country [96] 0 0
Italy
State/province [96] 0 0
CH
Country [97] 0 0
Italy
State/province [97] 0 0
FC
Country [98] 0 0
Italy
State/province [98] 0 0
MI
Country [99] 0 0
Italy
State/province [99] 0 0
PA
Country [100] 0 0
Italy
State/province [100] 0 0
PD
Country [101] 0 0
Italy
State/province [101] 0 0
PI
Country [102] 0 0
Italy
State/province [102] 0 0
PN
Country [103] 0 0
Italy
State/province [103] 0 0
PZ
Country [104] 0 0
Italy
State/province [104] 0 0
RM
Country [105] 0 0
Italy
State/province [105] 0 0
SS
Country [106] 0 0
Italy
State/province [106] 0 0
SV
Country [107] 0 0
Italy
State/province [107] 0 0
TO
Country [108] 0 0
Italy
State/province [108] 0 0
VR
Country [109] 0 0
Japan
State/province [109] 0 0
Aichi
Country [110] 0 0
Japan
State/province [110] 0 0
Ehime
Country [111] 0 0
Japan
State/province [111] 0 0
Gunma
Country [112] 0 0
Japan
State/province [112] 0 0
Hokkaido
Country [113] 0 0
Japan
State/province [113] 0 0
Hyogo
Country [114] 0 0
Japan
State/province [114] 0 0
Kagoshima
Country [115] 0 0
Japan
State/province [115] 0 0
Kanagawa
Country [116] 0 0
Japan
State/province [116] 0 0
Kumamoto
Country [117] 0 0
Japan
State/province [117] 0 0
Osaka
Country [118] 0 0
Japan
State/province [118] 0 0
Saitama
Country [119] 0 0
Japan
State/province [119] 0 0
Tokyo
Country [120] 0 0
Korea, Republic of
State/province [120] 0 0
Gyeonggi Do
Country [121] 0 0
Korea, Republic of
State/province [121] 0 0
Korea
Country [122] 0 0
Korea, Republic of
State/province [122] 0 0
Seoul
Country [123] 0 0
Lebanon
State/province [123] 0 0
Ashrafieh
Country [124] 0 0
Lebanon
State/province [124] 0 0
Beirut
Country [125] 0 0
Lebanon
State/province [125] 0 0
Saida
Country [126] 0 0
Mexico
State/province [126] 0 0
Monterrey
Country [127] 0 0
Mexico
State/province [127] 0 0
San Luis Potosi
Country [128] 0 0
Netherlands
State/province [128] 0 0
CE
Country [129] 0 0
Netherlands
State/province [129] 0 0
Terneuzen
Country [130] 0 0
Peru
State/province [130] 0 0
Lima
Country [131] 0 0
Romania
State/province [131] 0 0
Cluj
Country [132] 0 0
Romania
State/province [132] 0 0
Dolj
Country [133] 0 0
Romania
State/province [133] 0 0
Iasi
Country [134] 0 0
Russian Federation
State/province [134] 0 0
Arkhangelsk
Country [135] 0 0
Russian Federation
State/province [135] 0 0
Ryazan
Country [136] 0 0
Russian Federation
State/province [136] 0 0
St Petersburg
Country [137] 0 0
Spain
State/province [137] 0 0
Andalucia
Country [138] 0 0
Spain
State/province [138] 0 0
Cadiz
Country [139] 0 0
Spain
State/province [139] 0 0
Cataluna
Country [140] 0 0
Spain
State/province [140] 0 0
Catalunya
Country [141] 0 0
Spain
State/province [141] 0 0
Comunidad Valenciana
Country [142] 0 0
Spain
State/province [142] 0 0
Extremadura
Country [143] 0 0
Spain
State/province [143] 0 0
Galicia
Country [144] 0 0
Spain
State/province [144] 0 0
Islas Baleares
Country [145] 0 0
Spain
State/province [145] 0 0
Madrid
Country [146] 0 0
Spain
State/province [146] 0 0
Murcia
Country [147] 0 0
Spain
State/province [147] 0 0
Santa Cruz De Tenerife
Country [148] 0 0
Sweden
State/province [148] 0 0
Gavle
Country [149] 0 0
Sweden
State/province [149] 0 0
Oerebro
Country [150] 0 0
Sweden
State/province [150] 0 0
Vasteras
Country [151] 0 0
Taiwan
State/province [151] 0 0
Taipei
Country [152] 0 0
Thailand
State/province [152] 0 0
THA
Country [153] 0 0
Thailand
State/province [153] 0 0
Bangkok
Country [154] 0 0
United Kingdom
State/province [154] 0 0
Devon
Country [155] 0 0
United Kingdom
State/province [155] 0 0
Leicester
Country [156] 0 0
United Kingdom
State/province [156] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To determine whether treatment with alpelisib plus fulvestrant prolongs progression-free
survival compared to fulvestrant and placebo in men and postmenopausal women with hormone
receptor positive (HR+), HER2-negative advanced breast cancer, who received prior treatment
with an Aromatase Inhibitor either as (neo)adjuvant or for advanced disease.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02437318
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02437318